Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Phase 2

October 5, 2026

New Hope for Eczema: AbbVie Announces Positive Phase 2 Results for Zumilokibart

NYSE: $ABBV A Breakthrough in Atopic Dermatitis Treatment For millions of people living with moderate-to-severe atopic dermatitis (eczema), the search for more effective and convenient treatment options is ongoing. Recently, AbbVie provided an encouraging update regarding their clinical development program, announcing positive top-line results from the Phase 2 APEX study for their investigational therapy, zumilokibart.…

Clinical Trial

$ABBV, AbbVie, Atopic Dermatitis, clinical trials, dermatitis, dermatology, Phase 2, Zumilokibart
October 2, 2026

Pfizer’s Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

NYSE: $PFE NEW YORK–(BUSINESS WIRE) October 01, 2026 — Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its… Source: Read More

Clinical Trial

$PFE, Atopic Dermatitis, clinical trials, pfizer, Phase 2, Tilrekimig

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Subscribe For A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS. Subscribe to a premium report type below and you will receive reports with a longer outlook, allowing you to discover earlier entries to be positioned before a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email